仲佳，2015年毕业于北京大学医学部，肿瘤学博士，副主任医师，北京市医学基金会肺癌青年专业委员会秘书，中国老年肿瘤学会委员。致力于肺癌精准治疗及转化性研究。发表SCI论文数篇，曾多次在中国临床肿瘤学大会（CSCO）及世界肺癌大会（WCLC）等大会发言。社会任职北京市医学基金会肺癌青年专家委员会秘书中国老年学会老年肿瘤专业委员会委员北京抗癌协会肺癌专业委员会委员获奖荣誉csco35under35优秀选手医师报第七届医学家年会“十大医学新锐”科研成果1.YangX#,ZhongJ#,YuZ#,ZhuoM,ZhangM,ChenR,XiaX,ZhaoJ.GeneticandtreatmentprofilesofpatientswithconcurrentEpidermalGrowthFactorReceptor(EGFR)andAnaplasticLymphomaKinase(ALK)mutations.BMCCancer.2021Oct15;21(1):1107.（IF4.430）#共同第一作者2.WangL,ZhaoJ,AnT,WangY,ZhuoM,WuM,WangZ,LiJ,YangX,ChenH,ZhongJ*.ClinicalCharacteristicsandOutcomesofPatientsWithPrimaryMediastinalGermCellTumors:ASingle-CenterExperience.FrontOncol.2020Jul16;10:1137.（IF6.244）*通讯作者3.ZhongJ,ZhengQW,ZhaoJ,WangZP,WuMN,ZhuoML,WangYY,LiJJ,YangX,ChenHX,AnTT.[Therapeuticefficacyanalysisofimmunotherapyinsmallcelllungcancer].ZhonghuaZhongLiuZaZhi.2020Sep23;42(9):771-776.4.ZhongJ,GuoZ,FanL,ZhaoX,ZhaoB,CaoZ,ChengL,ShiY,LiX,ZhangY,AnT,WuM,WangY,ZhuoM,LiJ,YangX,ChenH,JiaB,ZhaoJ.ABCB1polymorphismpredictsthetoxicityandclinicaloutcomeoflungcancerpatientswithtaxane-basedchemotherapy.ThoracCancer.2019Nov;10(11):2088-2095.（IF3.500）5.ZhongJ,ZhengQ,AnT,ZhaoJ,WuM,WangY,ZhuoM,LiJ,ZhaoX,YangX,JiaB,ChenH,DongZ,WangJ,ChiY,ZhaiX,WangZ.Nomogramtopredictcause-specificmortalityinextensive-stagesmallcelllungcancer:Acompetingriskanalysis.ThoracCancer.2019Sep;10(9):1788-1797.(IF3.500)6.ZhongJ,ZhengQ,GaoE,DongZ,ZhaoJ,AnT,WuM,ZhuoM,WangY,LiJ,WangS,YangX,ChenH,JiaB,WangJ,WangZ.Influenceofbodymassindexonthetherapeuticefficacyofgemcitabinepluscisplatinandoverallsurvivalinlungsquamouscellcarcinoma.ThoracCancer.2018Feb;9(2):291-297.(IF3.500)7.ZhongJ,LiL,WangZ,BaiH,GaiF,DuanJ,ZhaoJ,ZhuoM,WangY,WangS,ZangW,WuM,AnT,RaoG,ZhuG,WangJ.PotentialResistanceMechanismsRevealedbyTargetedSequencingfromLungAdenocarcinomaPatientswithPrimaryResistancetoEpidermalGrowthFactorReceptor(EGFR)TyrosineKinaseInhibitors(TKIs).JThoracOncol.2017Dec;12(12):1766-1778....

擅长： 肺癌靶向治疗，肺癌免疫治疗，肺癌个体化治疗，临床研究咨询，胸腺肿瘤，胸膜间皮瘤